Literature DB >> 18540895

Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.

A Tagliaferri1, M Franchini, A Coppola, G F Rivolta, C Santoro, G Rossetti, G Feola, E Zanon, A Dragani, P Iannaccaro, P Radossi, P M Mannucci.   

Abstract

While primary prophylaxis is a well-established and recommended method of care delivery for children with severe haemophilia, fewer studies have documented the benefits of secondary prophylaxis started in adolescence or adulthood. To evaluate the role of secondary prophylaxis started in adolescent and adult severe haemophiliacs, a retrospective observational cohort study was conducted in 10 Italian Centres that investigated 84 haemophiliacs who had bled frequently and had thus switched from on-demand to prophylactic treatment during adolescence (n = 30) or adulthood (n = 54). The consumption of clotting factor concentrates, the orthopaedic and radiological scores, quality of life and disease-related morbidity were compared before and after starting secondary prophylaxis. Prophylaxis reduced the mean annual number of total and joint bleeds (35.8 vs. 4.2 and 32.4 vs. 3.3; P < 0.01) and of days lost from work/school (34.6 vs. 3.0, P < 0.01). A statistically significant reduction in the orthopaedic score was observed during prophylaxis in adolescents, but not in the whole cohort. Patients used more factor concentrates with corresponding higher costs on prophylaxis, but experienced a better quality of life. With respect to on-demand treatment, higher factor consumption and cost of secondary prophylaxis were balanced by marked clinical benefits and greater well-being in this cohort of adolescent/adult haemophiliacs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540895     DOI: 10.1111/j.1365-2516.2008.01791.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  31 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 2.  Secondary prophylaxis in adolescent and adult haemophiliacs.

Authors:  Annarita Tagliaferri; Caterina Di Perna; Gianna Franca Rivolta
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 3.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 4.  Present and future challanges in the treatment of haemophilia: a clinician's perspective.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

5.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

6.  The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia.

Authors:  Sweta Gupta; Azfar-E-Alam Siddiqi; J Michael Soucie; Marilyn Manco-Johnson; Roshni Kulkarni; Heidi Lane; Robina Ingram-Rich; Joan C Gill
Journal:  Br J Haematol       Date:  2013-02-22       Impact factor: 6.998

Review 7.  Current and evolving features in the clinical management of haemophilia.

Authors:  Antonio Coppola; Massimo Morfini; Ernesto Cimino; Antonella Tufano; Anna M Cerbone; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

8.  Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.

Authors:  M V Ragni; J G Yabes; P F Fogarty; N C Josephson; C M Kessler; A T Neff; L Raffini; K Brummel-Ziedins; C G Moore
Journal:  Haemophilia       Date:  2016-12-11       Impact factor: 4.287

9.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

Review 10.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.